Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study

• Published in: Journal of psychopharmacology (Oxford) Vol. 38; no. 3; p. 258
• Main Authors: Chen, Po-Yu, Chiu, Chih-Chiang, Chang, Chin-Kuo, Lu, Mong-Liang, Huang, Cho-Yin, Chen, Chun-Hsin, Huang, Ming-Chyi
• Format: Journal Article
• Language: English
• Published: United States 01.03.2024
• Subjects: Antipsychotic Agents - therapeutic use; Clozapine - therapeutic use; Cross-Sectional Studies; Humans; Orexins - therapeutic use; Prospective Studies; Schizophrenia - complications; Cognition; Treatment response; Clozapine; Treatment-resistant schizophrenia; Orexin-A

Clozapine is the primary antipsychotic (APD) for treatment-resistant schizophrenia (TRS). However, only 40% of patients with TRS respond to clozapine, constituting a subgroup of clozapine-resistant patients. Recently, the neuropeptide orexin-A was shown to be involved in the pathophysiology of schiz...